Evidence map›Paper›PMID 42602851›Full record

ArticleJournal of pharmaceutical analysis2026

Arctigenin discovered by high-throughput screening ameliorates doxorubicin-induced cardiotoxicity as a novel natural KEAP1-NRF2 inhibitor.

Xinyu Heng, Chao Ye, Shaohong Huang, Ke Zhang, Yankui Liu, Yueyue Wu, Ning Sun, Hai Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xinyu HengDepartment of Physiology and Pathophysiology, Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, China.
Chao YeDepartment of Physiology and Pathophysiology, Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, China.
Shaohong HuangDepartment of Physiology and Pathophysiology, Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, China.
Ke ZhangDepartment of Physiology and Pathophysiology, Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, China.
Yankui LiuDepartment of Physiology and Pathophysiology, Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, China.
Yueyue WuDepartment of Physiology and Pathophysiology, Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, China.
Ning SunDepartment of Physiology and Pathophysiology, Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, China.
Hai YangDepartment of Physiology and Pathophysiology, Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin (DOX), a widely used chemotherapeutic, is significantly limited by dose-dependent cardiotoxicity characterized by oxidative stress, mitochondrial dysfunction, and ferroptosis. Despite decades of research, dexrazoxane (DXZ) remains the only approved cardioprotectant, yet its clinical utility is constrained by potential reduction in efficacy and systemic toxicity. Effective alternatives are therefore urgently needed. Through high-throughput screening of a 960-compound natural product library, we identified arctigenin (ATG), a major bioactive compound from the Asian medicinal plant

Indexed as

ArctigeninDOX-Induced cardiotoxicityFerroptosisHigh-throughput screeningKEAP1-NRF2 protein-protein interaction (PPI)Oxidative stress

Identifiers

PMID42602851
PMCPMC13475220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.